Hepatitis E virus (HEV) is an important cause of viral hepatitis, especially in immunocompromised patients.
recently studied the incidence and course of HEV-infection in a large cohort of patients undergoing allogeneic hematopoietic SCT (HSCT). In contrast to previously published studies from our group 3 and others, 4 they identified a considerable number of patients with chronic HEV infection with a significant lethality. Therefore, they suggested pretransplant HEV screening for HSCT recipients. Reconsidering these important new results we now even extend our position, strongly suggesting HEV screening in HSCT.
We here report on a sibling HSCT donor with acute HEV infection at the time of PBSC harvest. The HLA-identical donor was an otherwise healthy man who was selected for his brother who suffered from progressive follicular lymphoma. At the day of leukapheresis, the donor presented with increased aminotransferase levels and bilirubinemia. Bilirubin was 38 mmol/L, alanine aminotransferase 1089 U/L, aspartate aminotransferase 828 U/L and g-glutamyltransferase 298 U/L ( Figure 1 ). Except for light scleral jaundice he had no other clinical symptoms. Standard serologic testing for hepatitis A, B, EBV and CMV were negative. Also HCV-RNA was negative. Other causes of hepatitis and liver damage were ruled out.
Although the incidence of HEV in Germany is low 5 and the donor did not belong to a risk population with a recent history of travel to countries endemic for HEV or contact with deer or pigs, we tested for HEV. Hepatitis E was diagnosed by positive results on anti-HEV-IgM and HEV-RNA detection (as described previously 6 ). The donor's HEV infection was diagnosed immediately before transplantation of the contagious allogeneic stem cells. Owing to the reported high lethality of HEV infection after HSCT and uncertain therapeutic options, 1, 7 we decided not to transplant the contaminated graft. Instead, as an escape strategy for the patient in BM aplasia after myeloablative conditioning, we decided to use autologous stem cells from the patient which had been stored earlier for high-dose therapy. The patient showed neutrophil recovery 10 days after autologous transplantation and is planed in case of further progress for a second attempt at sibling HSCT when his brother has overcome the HEV infection. Of note, when testing the donor's serum from pretransplant screening 2 weeks before stem cell donation, we were able to retrospectively detect HEV-RNA. At that time, mandatory laboratory tests such as liver enzymes and bilirubin were normal (alanine aminotransferase, 41 U/L) or only slightly elevated (aspartate aminotransferase 50 U/L; g-glutamyltransferase 73 U/L; bilirubin 29 mmol/L). This implies that the HEV infection could have been diagnosed before donor clearance and start of the patient's conditioning therapy.
In conclusion, this case serves as an example that HEV infection may occur in HSCT donors in a low-endemic country. HEV infection of the donor might be a potential life-threatening condition for the immunocompromised recipient, as lethal cases of HEV infection after HSCT have been reported. As this case is the first HEV infection described in a HSCT donor to our knowledge, precaution is warranted if donors present with either a risk profile for HEV or abnormal liver tests, and testing for HEV should be considered. AST GGT C l e a r a n c e H a r v e s t H a r v e s t Figure 1 . Changes in liver markers apartate aminotransferase (AST), alanine aminotransferase (ALT) and g-glutamyltransferase (GGT), and viral load of HEV. Liver biological markers were low at the time of donor clearance for allogeneic HSCT, but were increased at days 1 and 2 of PBSC harvest.
